Revolution Medicines (RVMD) Investor Update summary

Strategic partnership and funding update

• Announced a major partnership with Royalty Pharma, providing up to $2 billion in committed capital through a combination of synthetic royalty and corporate debt, with no equity dilution or loss of asset control.

• Approximately $1.25 billion of the funding is available at the company's discretion, contingent on achieving specific milestones.

• The funding structure includes tiered royalties on Diraxonrasib sales, with rates decreasing as sales increase and capped at zero above $8 billion in annual net sales.

• The $750 million senior-secured term loan is interest-only for six years, with tranches available post-FDA approval and upon reaching sales milestones.

• Synthetic royalty is divided into five $250 million tranches, with the first two tranches payable before FDA approval and the rest post-approval.

Commercialization and operational strategy

• The company will independently direct global development and commercialization, leveraging its growing U.S. and international capabilities.

• Plans to launch its RAS(ON) inhibitor portfolio, including Diraxonrasib, Elironrasib, and Zoldonrasib, targeting major cancers such as pancreatic, lung, and colorectal.

• U.S. market remains a strategic priority, with phased expansion into select international markets, particularly Europe and Japan.

• May consider focused regional partnerships for specific geographies, but broad commercial partnerships are now off the table.

• Funding supports an independent commercialization strategy to maximize patient reach and shareholder value.

Clinical development and portfolio plans

• The funding enables execution of ambitious, parallel late-stage clinical programs for RAS(ON) inhibitors, including combination strategies.

• No changes to current clinical development plans; two phase III trials are ongoing, with two more expected to initiate this year.

• Zoldonrasib development will proceed aggressively, with overlapping indications subject to the same royalty structure as Diraxonrasib.

• Pipeline includes daraxonrasib (multi-selective), elironrasib (G12C-selective), zoldonrasib (G12D-selective), and RMC-5127 (G12V-selective), with additional RAS(ON) mutant-selective inhibitors in earlier stages.

• Diraxonrasib recently received FDA breakthrough therapy designation for metastatic pancreatic cancer with KRAS G12 mutations.